🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance

RecruitingNAAges any - anyMaleNHS Lothian
NCT06117059 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer. The aim of the study is to ensure that the side effects of the 3-dose treatment are the same or potentially lower than those already published when using the 5-dose treatment as used in the UK PACE-B trial (NCT01584258). The name of this type of radiotherapy is Stereotactic Body Radiotherapy (SBRT) or participants may see it referred to as Stereotactic Ablative Radiotherapy (SABR). The study is a two-stage single arm Phase II study open to those Centres that use the RayPilot HypoCath tumour tracking system (Micropos Medical). This commercially available system was not available at the time of the original PACE-B study. The system acts like a Global Positioning Device (GPS) to continuously track the prostate positio

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * low and favorable intermediate NCCN Criteria patients * Prostate volume under 80cc * IPSS under 20 * Q-max above 10cc per second and urinary residual less than 150mls * No TURP * No hip replacements * No previous radiotherapy to the pelvis * No active second malignancy except skin SCC or BCC for the last 2 years * No history of inflammatory bowel disease * No co-morbid illness that would make compliance to treatment difficult * Able to give informed consent Exclusion Criteria: * T3a or above * Gleason 4+3=7 * PSA\>20ng/ml
💊

What it tests

  • 3 fractions of prostate SBRT
📍

Where

1 site
NHS Lothian
Edinburgh, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy